MIRXES-B (02629) Signs MOU with Watson to Establish RNA-Centric Preventive and Precision Medicine Platform

MIRXES-B (02629) announced that it has recently entered into a memorandum of understanding (MOU) with Yunnan Walvax Biotechnology Co., Ltd. (Watson). Under the agreement, both parties will leverage their complementary strengths to establish a strategic partnership focused on creating an RNA-centric preventive and precision medicine platform. The collaboration will cover joint development, clinical trials, regulatory approvals, as well as sales and distribution. The MOU is valid for two years from the signing date.

The scope of cooperation outlined in the MOU includes: (a) Establishing an RNA-centric preventive and precision medicine research center of excellence in Singapore, integrating MIRXES-B's proprietary disease RNA database with Watson's mRNA technology to advance research and commercialization of RNA-based diagnostics, vaccines, and therapeutics. (b) Accelerating clinical trials and regulatory approvals for existing and pipeline diagnostic products, vaccines, and therapeutics in the ASEAN region. (c) Setting up a sales and distribution platform in Singapore for existing and pipeline products, with a focus on serving ASEAN and select international markets. (d) Establishing a supply chain in Singapore to coordinate end-stage production, quality control, and commercial deployment of existing and pipeline products.

The board believes this partnership with Watson will generate significant strategic value, further solidifying MIRXES-B's position as a key player in the growing regional RNA diagnostics and therapeutics ecosystem. It will also expand the company's portfolio of early detection and preventive solutions while accelerating revenue growth.

This innovative RNA-centric platform will enable global institutions to collaborate with MIRXES-B and Watson in capturing regional opportunities while strategically positioning both companies in ASEAN and select international markets. The partnership is also expected to foster cross-border co-investment opportunities, enhance corporate visibility, deepen R&D capabilities, and contribute to the long-term growth and revenue diversification of the group.